The clinical-stage immuno-oncology (I-O) firm develops neoantigen-targeted therapies, a novel approach that it says delivers unrivaled patient and tumor specificity representing a new era in truly personal I-O therapeutics.
Lead candidate is NEO-PV-01, a personal neoantigen vaccine custom-designed for each individual patient. It is being evaluated in combination with Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) in melanoma, NSCLC and bladder cancer and with Merck's (NYSE:MRK) Keytruda (pembrolizumab) + chemo in NSCLC.
2018 Financials (Q1)($M): Operating Expenses: 16.8 (+75.5%); Net Loss: (19.7) (-65.0%); Cash Burn: (14.9) (-56.4%).
Previously: Neon Therapeutics teams up with Bristol-Myers in early-stage cancer trial (Dec. 15, 2015)
Subscribe for full text news in your inbox